Penilaian Risiko menggunakan Metode Failure Mode and Effects Analysis (FMEA) terkait Kontaminasi Silang pada Area Pengemasan di Industri Farmasi “XYZ”

Annisa Maulida Azzahra

doi:10.61132/obat.v2i5.600

Authors

Annisa Maulida Azzahra Universitas Padjadjaran

DOI:

https://doi.org/10.61132/obat.v2i5.600

Keywords:

Cross Contamination, Risk Assessment, FMEA

Abstract

Cross-contamination occurs due to other previously produced products, other rooms or areas producing different products, and particles from machinery or equipment. Quality risk management can be a preventive measure in reducing the potential for cross-contamination that occurs in the pharmaceutical industry. One part of quality risk management is risk assessment. One of the most common and effective methods is the Failure Mode and Effect Analysis (FMEA) method. This risk assessment is carried out using the stages of risk identification, risk analysis, and risk evaluation using categorization based on the Risk Priority Number (RPN). Based on the risk assessment using the FMEA method regarding cross-contamination in the Packaging area in the "XYZ" pharmaceutical industry, it can be concluded that the results of observations and interviews with operators and Packaging Supervisors identified 19 risks which were categorized as low, medium, high, and very high. Based on the results of the risk assessment obtained, the risk of cross-contamination that needs to be controlled is those with an RPN value of 30 ≤ RPN ≤ 60 (medium); 75 ≤ RPN ≤ 100 (high); RPN ≥ 150 (very high). Therefore, the "XYZ" pharmaceutical industry needs to determine and implement risk control measures. By adequately controlling the potential risk of cross-contamination, it will ensure the safety and quality of the products produced.

Downloads

Download data is not yet available.

References

Ali, H., & Hajela, R. (2011). Risk assessment & management in pharmaceutical industries: Vital requirement to ensure product quality. Journal of Pharmaceutical Research, 4(6), 1909–1910.

BPOM RI. (2018). Peraturan Kepala Badan Pengawas Obat dan Makanan Republik Indonesia Nomor 34 Tahun 2018 Tentang Cara Pembuatan Obat yang Baik. Badan Pengawas Obat dan Makanan Republik Indonesia, 70–73.

Cardoso, P., Flávia, M., & Kelen, S. (2018). Risk analysis evaluation of piroxicam 20 mg capsules manufacture process by FMEA technique. International Journal of Drug Regulatory Affairs, 6(1), 19–25.

Davison, M. (2003). Review of risk management. ACM SIGSAM Bulletin, 37(1), 28–29.

Delivery, D., & Mv, L. (2022). Quality risk management (QRM): A review. International Journal of Biology, Pharmacy and Allied Sciences, 11(10), 149–154.

Ismael, O. A., & Ahmed, M. I. (2020). Using quality risk management in pharmaceutical industries: A case study. Quality - Access to Success, 21(178), 106–113.

Khristi, A., & Khristi, P. (2018). A review on “failure mode and effects analysis – a tool of quality risk management” based on ICH Q9. International Journal of Research in Pharmacy and Chemistry, 8(1), 33–43.

Mandhare, T. A., Khuspe, P. R., Nangare, P. S., & Vyavhare, R. D. (2018). Quality risk management: A review. American Journal of PharmTech Research, 8(2), 56–86.

Mathia, E. (2013). Pharmaceutical product cross-contamination: Industrial and clinical pharmacy practice. Dar Es Salaam Medical Students’ Journal, 19(2), 17–19.

Nuchpho, P., Nansaarng, S., & Pongpullponsak, A. (2014). Risk assessment in the organization by using FMEA innovation: A literature review. International Conference on Education Reform, 8(March), 781–789. Available from https://www.researchgate.net/publication/264116818

Pharmaceutical Inspection Convention. (2021). Assessment of quality risk management implementation PI 038-2 Aide-Memories. Available from https://picscheme.org/docview/3823

Quinto, A., & Menezes. (2010). Design, validation, and control of sterile manufacturing facilities: A brief overview from the perspective of risk management and existing regulations. International Society for Pharmaceutical Engineering, 30(2), 1–9.

Sargent, E. V., Flueckiger, A., Barle, E. L., Luo, W., Molnar, L. R., Sandhu, R., et al. (2016). The regulatory framework for preventing cross-contamination of pharmaceutical products: History and considerations for the future. Regulatory Toxicology and Pharmacology, 79, S3–S10. Available from http://dx.doi.org/10.1016/j.yrtph.2016.05.029

Sasanti Handayani, R., Gitawati, R., Sistem dan Kebijakan Kesehatan, P., & Litbangkes, B. (2009). Persepsi konsumen apotek terhadap pelayanan apotek di tiga kota di Indonesia. Jurnal Ilmu Kefarmasian Indonesia, 13(1), 22–26.

Segismundo, A., & Augusto Cauchick Miguel, P. (2008). Failure mode and effects analysis (FMEA) in the context of risk management in new product development: A case study in an automotive company. International Journal of Quality & Reliability Management, 25(9), 899–912.

Shamseddin Alizadeh, S., Rasoulzadeh, Y., Moshashaei, P., Varmazyar, S., Sheikh Damanab, P., & Alizadeh, S., et al. (2015). Failure modes and effects analysis (FMEA) technique: A literature review. Science Journal Review, 4(1), 1–6. Available from www.Sjournals.com

Shebl, N. A., Franklin, B. D., & Barber, N. (2009). Is failure mode and effect analysis reliable? Journal of Patient Safety, 5(2), 86–94.

Susendi, N., Suparman, A., & Sopyan, I. (2021). Kajian metode root cause analysis yang digunakan dalam manajemen risiko di industri farmasi. Majalah Farmasetika, 6(4), 310.

Tanyous, J. N. (2019). Cleaning validation: Complete guide for health-based approach in chemical cross-contamination risk assessment. PDA Journal of Pharmaceutical Science and Technology, 73(2), 204–210.

Vázquez-Valencia, A., Santiago-Sáez, A., Perea-Pérez, B., Labajo-González, E., & Albarrán-Juan, M. E. (2018). Utilidad de análisis modal de fallos y efectos para mejorar la seguridad en la movilización del paciente crítico intubado. Revista Colombiana de Anestesiología, 46(1), 3–10.

World Health Organization (WHO). (2013). Annex 2 - WHO guidelines on quality risk management. WHO Expert Committee on Specifications for Pharmaceutical Preparations, 47(9), 61–92.

World Health Organization (WHO). (2013). Deviation handling and quality risk management. Available from http://www.who.int/immunization_standards/vaccine_quality/risk_july_2013.pdf

Wu, X., & Wu, J. (2021). The risk priority number evaluation of FMEA analysis based on random uncertainty and fuzzy uncertainty. Complexity, 2021.

Zameer, A. (2017). Critical risk assessment and management in pharmaceutical industry. Available from http://digitalcommons.harrisburgu.edu/pmgt_dandt/13

Zandieh, M. (2020). Risk assessment of clean room used in pharmaceutical industries in design, manufacturing, equipping, and operating phases by FMEA based on some chemical engineering concepts. Archives of Pharmacy Practice, 11, 39–45.